Omega Therapeutics (OMGA)
(Delayed Data from NSDQ)
$1.55 USD
+0.03 (1.97%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.56 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Omega Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 73 | 125 | 225 | 23 | -99,999 |
Receivables | 6 | 1 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 10 | 12 | 4 | 1 | NA |
Total Current Assets | 90 | 138 | 229 | 24 | NA |
Net Property & Equipment | 5 | 4 | 4 | 3 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 1 | 0 | 1 | NA |
Total Assets | 204 | 146 | 233 | 28 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 3 | 2 | 1 | NA |
Current Portion Long-Term Debt | 4 | 3 | 0 | 3 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 8 | 14 | 9 | 3 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 2 | 0 | 0 | 0 | NA |
Total Current Liabilities | 27 | 22 | 12 | 8 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 15 | 17 | 20 | 9 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 6 | 0 | 1 | 1 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 75 | NA |
Total Liabilities | 146 | 40 | 33 | 93 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 393 | 344 | 335 | 2 | NA |
Retained Earnings | -335 | -237 | -135 | -66 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 58 | 106 | 201 | -65 | NA |
Total Liabilities & Shareholder's Equity | 204 | 146 | 233 | 28 | NA |
Total Common Equity | 58 | 106 | 201 | -65 | 0 |
Shares Outstanding | 55.10 | 48.00 | 47.70 | NA | NA |
Book Value Per Share | 1.05 | 2.21 | 4.21 | 0.00 | 0.00 |
Fiscal Year End for Omega Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 46 | 60 | 73 | 89 | 113 |
Receivables | 1 | 1 | 6 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 10 | 10 | 12 | 11 |
Total Current Assets | 56 | 71 | 90 | 102 | 125 |
Net Property & Equipment | 5 | 5 | 5 | 5 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 168 | 184 | 204 | 218 | 229 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 2 | 6 |
Current Portion Long-Term Debt | 4 | 4 | 4 | 4 | 8 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 8 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 2 | 0 | 1 |
Total Current Liabilities | 26 | 25 | 27 | 27 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 13 | 14 | 15 | 16 | 12 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 6 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 142 | 142 | 146 | 142 | 133 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 397 | 396 | 393 | 390 | 388 |
Retained Earnings | -371 | -355 | -335 | -314 | -292 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 26 | 41 | 58 | 76 | 96 |
Total Liabilities & Shareholder's Equity | 168 | 184 | 204 | 218 | 229 |
Total Common Equity | 26 | 41 | 58 | 76 | 96 |
Shares Outstanding | 55.10 | 55.10 | 55.10 | 55.10 | 55.00 |
Book Value Per Share | 0.48 | 0.75 | 1.05 | 1.38 | 1.74 |